Author:
Donadelli M,Dando I,Zaniboni T,Costanzo C,Dalla Pozza E,Scupoli M T,Scarpa A,Zappavigna S,Marra M,Abbruzzese A,Bifulco M,Caraglia M,Palmieri M
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Cell Biology,Cellular and Molecular Neuroscience,Immunology
Reference40 articles.
1. Li J, Merl MY, Chabot J, Saif MW . Updates of adjuvant therapy in pancreatic cancer: where are we and where are we going? Highlights from the ‘2010 ASCO Annual Meeting’. Chicago, IL, USA. JOP 2010; 11: 310–312.
2. Neoptolemos JP, Cunningham D, Friess H, Bassi C, Stocken DD, Tait DM et al. Adjuvant therapy in pancreatic cancer: historical and current perspectives. Ann Oncol 2003; 14: 675–692.
3. Burris III HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403–2413.
4. Laurent A, Nicco C, Chereau C, Goulvestre C, Alexandre J, Alves A et al. Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res 2005; 65: 948–956.
5. Donadelli M, Costanzo C, Beghelli S, Scupoli MT, Dandrea M, Bonora A et al. Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. Biochim Biophys Acta 2007; 1773: 1095–1106.
Cited by
185 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献